Alcidion (ASX:ALC) - Managing Director, Kate Quirke (left)
Managing Director, Kate Quirke (left)
Source: The CEO Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) has signed a contract with East Lancashire Hospitals NHS Trust for its Patientrack and Smartpage platforms, valued at $2.2 million
  • Patientrack will be used by nurses at patients’ bedsides to capture vital signs, automatically calculating a patient’s early warning score
  • Smartpage will then be integrated with Patientrack to alert teams if action needs to be taken for patient care
  • The contract will see the platforms deployed at all five hospital sites over five years
  • Alcidion is up 5.36 per cent, trading at 29.5 cents

Alcidion Group (ALC) has signed a contract with East Lancashire Hospitals NHS Trust for Patientrack and Smartpage, valued at $2.2 million.

The contract will see the platforms deployed at all five hospital sites over five years.  

East Lancashire Trust is a large, integrated health care organisation of 8000 staff, providing acute, secondary and community healthcare for the 530,000 residents of East Lancashire and Blackburn.

Patientrack will be used by nurses for crucial observations and will be integrated directly with devices used at patients’ bedsides to capture vital signs, automatically calculating a patient’s early warning score.

Smartpage is Alcidion’s smartphone and web-based secure messaging system for hospital communication and task management. This will be deployed and integrated with Patientrack to push alerts to clinical teams if they need to take action for patient care.

“Patientrack, which has delivered impressive results for patient safety in dozens of other NHS hospitals, accompanied by Smartpage, will be an important part of that digital roadmap and the deployment of our local EPR,” said East Lancashire Hospitals NHS Trust Chief Information Officer, Mark Johnson.

“We are confident that the experiences and learning from the deployment will support the regional objectives of having consolidated information for all patients. These are mobile technologies that our clinicians want to use, that can help to alleviate pressure and remove manual processes, and that can have a very immediate impact on patient outcomes and safety.”

Alcidion is up 5.36 per cent, trading at 29.5 cents at 10:40 am AEDT.

ALC by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…